{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T12:49:39Z","timestamp":1783255779068,"version":"3.54.6"},"reference-count":119,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.jaad.2012.04.036","type":"journal-article","created":{"date-parts":[[2012,6,21]],"date-time":"2012-06-21T16:54:11Z","timestamp":1340297651000},"page":"1349-1361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management"],"prefix":"10.1016","volume":"67","author":[{"given":"Amanda","family":"Abramson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Menter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Perrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2012.04.036_bib1","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.3899\/jrheum.081324","article-title":"Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-\u03b1 therapy","volume":"36","author":"Chung","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib2","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1002\/hep.22946","article-title":"National Institutes of Health consensus development conference statement: management of hepatitis B","volume":"49","author":"Sorrell","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jaad.2012.04.036_bib3","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199712113372406","article-title":"Hepatitis B virus infection","volume":"337","author":"Lee","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2012.04.036_bib4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jaad.2012.04.036_bib5","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis, section 1: overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib6","first-page":"111","article-title":"Biologics in the management of psoriasis","volume":"2","author":"Bahner","year":"2009","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib7","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.1365-2133.2011.10494.x","article-title":"Medical comorbidity associated with psoriasis in adults: a population-based study","volume":"165","author":"Yang","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2036.2009.04112.x","article-title":"Review article: chronic viral infection in the anti-tumor necrosis factor therapy era in inflammatory bowel disease","volume":"31","author":"Shale","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaad.2012.04.036_bib9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2133.2009.09505.x","article-title":"British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009","volume":"161","author":"Smith","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/0885066604267854","article-title":"Serious infections associated with anticytokine therapies in the rheumatic diseases","volume":"19","author":"Giles","year":"2004","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.jaad.2012.04.036_bib11","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2007.10.011","article-title":"Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection","volume":"38","author":"Carroll","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2012.04.036_bib12","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Cytokine pathways and joint inflammation in rheumatoid arthritis","volume":"344","author":"Choy","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2012.04.036_bib13","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nm0595-442","article-title":"Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis","volume":"1","author":"Gottlieb","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2012.04.036_bib14","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/eji.1830250551","article-title":"The role of gamma delta T cells in priming macrophages to produce tumor necrosis factor-alpha","volume":"25","author":"Nishimura","year":"1995","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaad.2012.04.036_bib15","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1056\/NEJM199704103361506","article-title":"Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases","volume":"336","author":"Barnes","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2012.04.036_bib16","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1084\/jem.168.3.941","article-title":"Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques","volume":"168","author":"Gottlieb","year":"1988","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2012.04.036_bib17","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/archderm.1991.01680050071006","article-title":"Interleukin 1 alpha, tumor necrosis factor alpha, and interferon gamma in psoriasis","volume":"127","author":"Gomi","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib18","first-page":"129","article-title":"Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis","volume":"138","author":"Nickoloff","year":"1991","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaad.2012.04.036_bib19","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/acr.20130","article-title":"Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative\/anti-hepatitis B core antigen positive) with rheumatic diseases","volume":"62","author":"Caporali","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jaad.2012.04.036_bib20","first-page":"645","article-title":"Tumor necrosis factor-alpha antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients","volume":"164","author":"Prignano","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib21","first-page":"241","article-title":"Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis","volume":"223","author":"Herbein","year":"2000","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.jaad.2012.04.036_bib22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.immunol.19.1.65","article-title":"Noncytolytic control of viral infections by the innate and adaptive immune response","volume":"19","author":"Guidotti","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaad.2012.04.036_bib23","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1046\/j.1365-2249.1999.00812.x","article-title":"Meyer zum B\u00fcschenfelde KH. HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines","volume":"115","author":"Schlaak","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaad.2012.04.036_bib24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3748\/wjg.v13.i1.82","article-title":"Pathogenesis of hepatitis B virus infection","volume":"13","author":"Baumert","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jaad.2012.04.036_bib25","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/jcp.47.12.1112","article-title":"Hepatic expression of tumor necrosis factor-alpha in chronic hepatitis B virus infection","volume":"47","author":"Hussain","year":"1994","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jaad.2012.04.036_bib26","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/0140-6736(90)90475-K","article-title":"Spontaneous production of tumor necrosis factor alpha and interleukin-1 beta during interferon-alpha treatment of chronic HBV infection","volume":"335","author":"Daniels","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2012.04.036_bib27","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10067-010-1523-2","article-title":"Use of tumor necrosis factor \u03b1 inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action","volume":"29","author":"Carroll","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib28","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1468-3083.2010.03754.x","article-title":"Safety of anti-tumor necrosis factor-\u03b1 agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature","volume":"25","author":"Fotiadou","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2012.04.036_bib29","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3899\/jrheum.081246","article-title":"Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature","volume":"36","author":"Zingarelli","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib30","doi-asserted-by":"crossref","first-page":"32633","DOI":"10.1074\/jbc.M400642200","article-title":"Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling","volume":"279","author":"Banno","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaad.2012.04.036_bib31","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/135965350300800616","article-title":"Unique keratinocyte-specific effects of interferon-gamma that protect skin from viruses, identified using transcriptional profiling","volume":"8","author":"Banno","year":"2003","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jaad.2012.04.036_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1074-7613(00)80295-2","article-title":"Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes","volume":"4","author":"Guidotti","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.jaad.2012.04.036_bib33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0140-6736(90)91866-9","article-title":"Tumor necrosis factor to treat chronic hepatitis B virus infection","volume":"336","author":"Sheron","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2012.04.036_bib34","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/nrrheum.2010.156","article-title":"Therapy: are TNF blockers safe for patients with hepatitis B virus infection?","volume":"6","author":"Ramos-Casals","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib35","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1084\/jem.191.8.1263","article-title":"Intrahepatic T cells in hepatitis B: viral control versus liver cell injury","volume":"191","author":"Rehermann","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2012.04.036_bib36","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3748\/wjg.v17.i12.1553","article-title":"Diagnostic strategy for occult hepatitis B virus infection","volume":"17","author":"Ocana","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jaad.2012.04.036_bib37","series-title":"Sleisinger and Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis and management","first-page":"1287","article-title":"Hepatitis B and D","author":"Perrillo","year":"2010"},{"issue":"Suppl","key":"10.1016\/j.jaad.2012.04.036_bib38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1478-3231.2010.02396.x","article-title":"The difficulties of managing severe hepatitis B virus reactivation","volume":"31","author":"Roche","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jaad.2012.04.036_bib39","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s10157-011-0464-7","article-title":"Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy","volume":"15","author":"Ohishi","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jaad.2012.04.036_bib40","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.3748\/wjg.v17.i12.1543","article-title":"Pathogenesis of occult chronic hepatitis B virus infection","volume":"17","author":"de la Fuente","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jaad.2012.04.036_bib41","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3748\/wjg.v17.i12.1563","article-title":"Management of occult hepatitis B virus infection: an update for the clinician","volume":"17","author":"Lledo","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jaad.2012.04.036_bib42","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2012.04.036_bib43","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","article-title":"Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study","volume":"100","author":"Lok","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2012.04.036_bib44","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/jmv.2060","article-title":"Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis","volume":"65","author":"Yeo","year":"2001","journal-title":"J Med Virol"},{"key":"10.1016\/j.jaad.2012.04.036_bib45","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/ard.2005.043257","article-title":"Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies","volume":"65","author":"Calabrese","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2012.04.036_bib46","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jcv.2004.10.006","article-title":"HBV reactivation after kidney transplantation","volume":"32","author":"Berger","year":"2005","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jaad.2012.04.036_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar2868","article-title":"Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients","volume":"11","author":"Charpin","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaad.2012.04.036_bib48","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/j.1440-1746.2010.06243.x","article-title":"Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management","volume":"25","author":"Lubel","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib49","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1445-5994.2007.01479.x","article-title":"Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management","volume":"37","author":"Lubel","year":"2007","journal-title":"Intern Med J"},{"key":"10.1016\/j.jaad.2012.04.036_bib50","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/gast.2001.22461","article-title":"Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease","volume":"120","author":"Perrillo","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2012.04.036_bib51","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B","volume":"50","author":"European Association for the Study of the Liver","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib52","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1346-8138.2011.01434.x","article-title":"Use of anti-tumor necrosis factor-\u03b1 therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan","volume":"39","author":"Cho","year":"2011","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib53","first-page":"9","article-title":"Psoriatics in Norway: a questionnaire study on health status, contact with paramedical professions, and alcohol and tobacco consumption","volume":"142","author":"Braathen","year":"1989","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"key":"10.1016\/j.jaad.2012.04.036_bib54","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/bmj.300.6727.780","article-title":"Alcohol intake: a risk factor for psoriasis in young and middle aged men?","volume":"300","author":"Poikolainen","year":"1990","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2012.04.036_bib55","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00403-006-0703-z","article-title":"Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis","volume":"298","author":"Sommer","year":"2006","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2012.04.036_bib56","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.bjc.6601699","article-title":"Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy","volume":"90","author":"Yeo","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaad.2012.04.036_bib57","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.3748\/wjg.v17.i12.1531","article-title":"Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy","volume":"17","author":"Manzano-Alonso","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jaad.2012.04.036_bib58","first-page":"621","article-title":"Impact of immunosuppression and chemotherapy on reactivation of viral hepatitis","volume":"21","author":"Fallahian","year":"2010","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.jaad.2012.04.036_bib59","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7326\/0003-4819-148-7-200804010-00008","article-title":"Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy","volume":"148","author":"Loomba","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2012.04.036_bib60","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1136\/ard.2009.127233","article-title":"Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection","volume":"69","author":"Vassilopoulos","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2012.04.036_bib61","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.jaad.2012.04.036_bib62","first-page":"S3","article-title":"EASL international consensus conference on hepatitis B; 13-14 September, 2002, Geneva, Switzerland; consensus statement (long version)","volume":"39","author":"de Franchis","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib63","first-page":"e2009025","article-title":"Management of HBV infection during immunosuppressive treatment","volume":"1","author":"Marzano","year":"2009","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.jaad.2012.04.036_bib64","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000183731","article-title":"Oncologists and hepatitis B: a survey to determine current level of awareness and practice of antiviral prophylaxis to prevent reactivation","volume":"55","author":"Khokhar","year":"2009","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jaad.2012.04.036_bib65","first-page":"1","article-title":"Recommendations for identification and public health management of persons with chronic hepatitis B virus infection","volume":"57","author":"Weinbaum","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jaad.2012.04.036_bib66","doi-asserted-by":"crossref","first-page":"31e1","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib67","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib68","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/ard.2009.112136","article-title":"Risk of elevated liver enzymes associated with TNF inhibitor utilization in patients with rheumatoid arthritis","volume":"69","author":"Sokolove","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2012.04.036_bib69","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","article-title":"Construction and initial characterization of a mouse-human chimeric anti-TNF antibody","volume":"30","author":"Knight","year":"1993","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jaad.2012.04.036_bib70","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2012.04.036_bib71","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/cyto.1995.0029","article-title":"Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions","volume":"7","author":"Scallon","year":"1995","journal-title":"Cytokine"},{"key":"10.1016\/j.jaad.2012.04.036_bib72","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1067\/mjd.2003.10","article-title":"Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris","volume":"48","author":"Gottlieb","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib73","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.4049\/jimmunol.156.4.1646","article-title":"In\u00a0vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis: short term cellular and molecular effects","volume":"156","author":"Lorenz","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2012.04.036_bib74","first-page":"13","article-title":"Clinical pharmacokinetics of tumor necrosis factor antagonists","volume":"74","author":"Nestorov","year":"2005","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.jaad.2012.04.036_bib75","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semarthrit.2005.01.004","article-title":"Clinical pharmacokinetics of TNF antagonists: how do they differ?","volume":"34","author":"Nestorov","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2012.04.036_bib76","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2004.040675","article-title":"Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis","volume":"53","author":"Esteve","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.jaad.2012.04.036_bib77","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2133.2008.08732.x","article-title":"Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials","volume":"159","author":"Schmitt","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib78","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2133.2008.08673.x","article-title":"Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials","volume":"159","author":"Brimhall","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib79","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0016-5085(75)80054-0","article-title":"Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders","volume":"68","author":"Wands","year":"1975","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2012.04.036_bib80","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(75)90897-1","article-title":"Fulminant hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy","volume":"2","author":"Galbraith","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2012.04.036_bib81","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib82","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0149-2918(03)80164-9","article-title":"Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study","volume":"25","author":"Weisman","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaad.2012.04.036_bib83","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib84","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2012.04.036_bib85","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrd2196","article-title":"Biologic therapies in rheumatology: lessons learned, future directions","volume":"6","author":"Strand","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaad.2012.04.036_bib86","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/0091270004273321","article-title":"Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein","volume":"45","author":"Zhou","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jaad.2012.04.036_bib87","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2125.2006.02581.x","article-title":"Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis","volume":"62","author":"Nestorov","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaad.2012.04.036_bib88","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaad.2012.04.036_bib89","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1136\/ard.2003.011023","article-title":"Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review","volume":"62","author":"Keller","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2012.04.036_bib90","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1345\/aph.19126","article-title":"The pharmacokinetics of etanercept in healthy volunteers","volume":"34","author":"Korth-Bradley","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaad.2012.04.036_bib91","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clindermatol.2007.10.030","article-title":"Tumor necrosis factor antagonists in the therapy of psoriasis","volume":"26","author":"M\u00f6ssner","year":"2008","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib92","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","article-title":"A randomized trial of etanercept as monotherapy for psoriasis","volume":"139","author":"Gottlieb","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib93","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib94","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2012.04.036_bib95","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1157\/13087150","article-title":"Reactivation of hepatitis B treated with adefovir after infliximab administration","volume":"126","author":"N\u00fa\u00f1ez-Rodr\u00edguez","year":"2006","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.jaad.2012.04.036_bib96","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jaad.2008.09.057","article-title":"Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection","volume":"60","author":"Conde-Taboada","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib97","doi-asserted-by":"crossref","first-page":"b508","DOI":"10.1136\/bmj.b508","article-title":"Life threatening liver disease during treatment with monoclonal antibodies","volume":"338","author":"Kaiser","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2012.04.036_bib98","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1365-2133.2010.09714.x","article-title":"Safety of antitumor necrosis factor-alpha therapy in psoriatic patients with hepatitis B virus infection","volume":"162","author":"Nosotti","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2012.04.036_bib99","first-page":"23","article-title":"Hepatitis-B reactivation during treatment with tumor necrosis factor-\u03b1 blocker adalimumab in a patient with psoriasis arthritis","volume":"137","author":"Kouba","year":"2012","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.jaad.2012.04.036_bib100","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/hep.22518","article-title":"Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?","volume":"48","author":"Papatheodoridis","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jaad.2012.04.036_bib101","first-page":"285","article-title":"Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease","volume":"25","author":"Cassano","year":"2011","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.jaad.2012.04.036_bib102","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","article-title":"Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases","volume":"90","author":"P\u00e9rez-Alvarez","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaad.2012.04.036_bib103","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/gut.2010.208413","article-title":"Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy","volume":"59","author":"Loras","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.jaad.2012.04.036_bib104","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1002\/hep.22945","article-title":"Reactivation of hepatitis B","volume":"49","author":"Hoofnagle","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jaad.2012.04.036_bib105","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2004.05.161","article-title":"Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy","volume":"22","author":"Yeo","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2012.04.036_bib106","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/hep.22106","article-title":"A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial","volume":"47","author":"Hsu","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jaad.2012.04.036_bib107","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1080\/10428190801975568","article-title":"Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy","volume":"49","author":"Cil","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaad.2012.04.036_bib108","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1478-3231.2004.0964.x","article-title":"Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration","volume":"24","author":"Dai","year":"2004","journal-title":"Liver Int"},{"key":"10.1016\/j.jaad.2012.04.036_bib109","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1182\/blood-2002-07-1976","article-title":"Prophylactic lamivudine therapy for hepatitis B patients undergoing immunosuppressive therapy","volume":"100","author":"Lau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2012.04.036_bib110","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1046\/j.1365-2141.2001.03099.x","article-title":"Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy","volume":"115","author":"Rossi","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2012.04.036_bib111","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1572-0241.1999.00808.x","article-title":"Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection","volume":"94","author":"Ahmed","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaad.2012.04.036_bib112","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10549-004-0725-1","article-title":"Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients","volume":"88","author":"Yeo","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jaad.2012.04.036_bib113","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00004836-200307000-00017","article-title":"Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with lamivudine","volume":"37","author":"Simpson","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jaad.2012.04.036_bib114","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1046\/j.1365-2036.2002.01364.x","article-title":"Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients","volume":"16","author":"Lim","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaad.2012.04.036_bib115","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ajh.20471","article-title":"Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy\u2013a prospective case series","volume":"80","author":"Vassiliadis","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaad.2012.04.036_bib116","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1478-3231.2007.01618.x","article-title":"Lamivudine prophylaxis is\u00a0effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis","volume":"28","author":"Martyak","year":"2008","journal-title":"Liver Int"},{"key":"10.1016\/j.jaad.2012.04.036_bib117","doi-asserted-by":"crossref","unstructured":"Kuwabara H, Fukuda A, Tsuda Y, Shibayama Y. Precore mutant hepatitis B virus-associated fulminant hepatitis during infliximab therapy for rheumatoid arthritis. Clin Rheumatol doi: 10.1007\/s10067-010-1438-y. Published online April 9, 2010.","DOI":"10.1007\/s10067-010-1438-y"},{"key":"10.1016\/j.jaad.2012.04.036_bib118","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/ibd.20216","article-title":"Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease","volume":"13","author":"Colbert","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2012.04.036_bib119","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/oxfordjournals.aje.a114680","article-title":"Prevention of perinatal transmission of hepatitis B virus: the sensitivity, specificity, and predictive value of the recommended screening questions to detect high-risk women in an obstetric population","volume":"126","author":"McQuillan","year":"1987","journal-title":"Am J Epidemiol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962212004598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962212004598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:26:42Z","timestamp":1759271202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962212004598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":119,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0190962212004598"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2012.04.036","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2012.04.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}